共 50 条
- [41] ANALYSIS OF INDIVIDUAL-LEVEL ASSOCIATION OF PROGRESSION-FREE SURVIVAL (PFS) AND TIME TO TREATMENT FAILURE (TTF) WITH OVERALL SURVIVAL (OS) FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA PATIENTS IN THE CHECKMATE 214 TRIALVALUE IN HEALTH, 2021, 24 : S20 - S20Siliman, G.Kanters, S.Fazeli, M. S.Pourrahmat, M. M.Ejzykowicz, F.Kurt, M.
- [43] A PHASE 3 STUDY (COSMIC-313) OF CABOZANTINIB IN COMBINATION WITH NIVOLUMAB AND IPILIMUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA OF INTERMEDIATE OR POOR RISKJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A209 - A209Choueiri, ToniAlbiges, LaurencePowles, ThomasMohamed, NehalWang, FongMotzer, Robert
- [44] Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Zhu, MinTang, RuiDoshi, SameerOliner, Kelly S.Kathman, StevenGisleskog, Per OlssonDubey, SaritaJiang, YizhouDonehower, Ross C.Iveson, TimothyLoh, Elwyn
- [45] Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation StudyJOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 391 - +Callahan, Margaret K.Kluger, HarrietPostow, Michael A.Segal, Neil H.Lesokhin, AlexanderAtkins, Michael B.Kirkwood, John M.Krishnan, SubaBhore, RafiaHorak, ChristineWolchok, Jedd D.Sznol, Mario
- [46] A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Choueiri, Toni K.Albiges, LaurencePowles, ThomasScheffold, ChristianWang, FongMotzer, Robert J.
- [47] Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN)JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA9503 - LBA9503Robert, CarolineDutriaux, CarolineOppong, Felix BoakyeKicinski, MichalRoutier, EmilieNeidhardt, Eve-MarieDurando, XavierBaroudjian, BarouyrSaiag, PhilippeGaudy-Marqueste, CarolineAscierto, Paolo AntonioArance, Ana MariaRussillo, MichelangeloPerrot, Jean-LucGovaerts, Anne-sophieBuhrer, EmanuelSchilling, BastianMandala, MarioLorigan, Paulvan Akkooi, Alexander Christopher Jonathan
- [48] Exposure-response (E-R) analysis of efficacy of pegvorhyaluronidase alfa (PEGPH20) in combination with nab-paclitaxel plus gemcitabine (AG) in patients (Pts) with metastatic pancreatic ductal adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Liu, YongBullock, Andrea J.Passarell, JulieBihorel, SebastienFiedler-Kelly, JillHeineman, Thomas C.Sekulovich, Rose E.
- [49] DASATINIB PHARMACOKINETICS AND EXPOSURE-RESPONSE (E-R): RELATIONSHIPS TO EFFICACY AND SAFETY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (CML-CP)HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 227 - 227Nicaise, C.Wang, X.Roy, A.Pfister, M.Chen, T. T.Bleickardt, E.Hochhaus, A.Shah, N. P.Nicolini, F. E.Clark, R. E.Saglio, G.Kantarjian, H.
- [50] Population Modeling of Exposure-Response (E-R) for Select Safety Endpoints in Non-Small Cell Lung Cancer Patients Receiving LorlatinibJOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S59 - S59Chen, JosephRuiz, AnaJames, LeeThurm, HolgerPeltz, GersonPithavala, Yazdi K.